Ipsen appoints Keira Driansky as EVP, President of North America
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningen
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases